

## EDUCATION

---

|                                                                                                                                          |                                         |
|------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------|
| <b>Doctor of Philosophy (PhD)</b> , Clinical Research<br>University of Jamestown, College of Graduate and Professional Studies           | Expected, May 2026<br>Jamestown, ND     |
| <b>Master of Business Administration (MBA)</b> , Health, Technology, and Innovation (HTI) pathway<br>Johns Hopkins Carey Business School | Expected, May 2025<br>Baltimore, MD     |
| <b>Master of Health Administration (MHA)</b><br>Louisiana State University Shreveport                                                    | Expected, May 2025<br>Shreveport, LA    |
| <b>Master of Public Health (MPH)</b> , Epidemiology and Public Health<br>University of Nicosia Medical School                            | Expected, March 2024<br>Nicosia, Cyprus |
| <b>Medical Degree (MD)</b><br>University of Crete, School of Medicine                                                                    | July 2017<br>Heraklion, Greece          |

## WORK EXPERIENCE

---

|                                                                                                      |                                                                         |
|------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------|
| <b>Translational Medical Lead, GU Oncology<br/>Scientist, Translational Medicine</b><br>Natera, Inc. | March 2024 – Present<br>April 2022 – Present<br>San Carlos, CA (Remote) |
|------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------|

- Spearheaded translational research initiatives, emphasizing the clinical application of somatic molecular testing in oncology, directly supporting the development and validation of cutting-edge diagnostic technologies for cancer management.
- Led the conceptualization and execution of Phase II-III clinical trials focused on circulating tumor DNA (ctDNA) analysis, driving forward the integration of molecular diagnostics in personalized oncology care.
- Played a pivotal role in the strategic use of real-world evidence (RWE) for the enhancement of molecular oncology testing frameworks, contributing to pivotal regulatory submissions and supporting evidence-based reimbursement strategies.
- Established and maintained collaborative relationships with premier cancer centers and Key Opinion Leaders (KOLs), facilitating the adoption of novel diagnostic solutions and ensuring alignment with the latest clinical research and oncology practices.
- Offered clinical and scientific guidance to cross-functional teams, enhancing product development with insights into oncologist needs and the practical application of somatic genetic testing in clinical settings.
- Championed the submission of Molecular Diagnostics (MoDx) dossiers, ensuring the inclusion of comprehensive data analyses to substantiate the clinical utility and reimbursement of molecular tests across various cancer types, including muscle-invasive bladder, gastroesophageal, testicular, and pancreatic cancers.
- Engaged in significant investigator-initiated studies, contributing to the expansion of test indications through rigorous validation and outcomes assessment, thereby elevating the scientific credibility of our testing platforms.

|                                                               |                                        |
|---------------------------------------------------------------|----------------------------------------|
| <b>Senior Scientist, Biology</b><br>Sirius Therapeutics, Inc. | April 2022– October 2022<br>Boston, MA |
|---------------------------------------------------------------|----------------------------------------|

- Orchestrated the research and clinical development pipeline as an executive, streamlining operations for a recently acquired startup.
- Led a team of six scientists, overseeing hiring, training, and professional development, while managing budgets, contracts, and equipment procurement.
- Spearheaded the validation process and Investigational New Drug (IND) submissions for two novel RNA drugs, enhancing the company's therapeutic portfolio.
- Administered an artificial intelligence database designed for the clinical trial analysis of RNA drugs, optimizing data-driven decision-making processes.

|                                                                |                                                    |
|----------------------------------------------------------------|----------------------------------------------------|
| <b>Medical &amp; Research Strategic Consultant</b><br>Docus.ai | February 2022 – Present<br>Middletown, DE (Remote) |
|----------------------------------------------------------------|----------------------------------------------------|

- Advised on the development and implementation of research and trial policies for an AI-powered, HIPAA-compliant telemedicine platform targeting developing countries.
- Worked in tandem with the CEO and CSO to enhance the telemedicine service, facilitating connections between top US doctors and hospitals in developing regions.
- Offered expert scientific guidance on the integration of new clinical research methodologies and trial policies to maximize the platform's global health impact.

**Resident Intern, Internal Medicine**  
**Research Scientist, Cancer Biology & Epigenetics**  
Johns Hopkins School of Medicine

May 2021 – April 2022  
March 2021 – February 2022  
Baltimore, MD

- Delivered direct patient care and collaborated with multidisciplinary teams to devise and execute comprehensive treatment strategies, enhancing patient outcomes.
- Conducted groundbreaking research on PI3K/AKT signaling pathways and their influence on RNA regulation in breast cancer, utilizing both pre-clinical and clinical multi-omics models.
- Mentored and managed a team of five Master's level research assistants, fostering their growth and ensuring their professional advancement in the field.

**Clinical Research Associate, Cancer Immunotherapy**  
Ohio State University Comprehensive Cancer Center - James Cancer Hospital

November 2019 – February 2022  
Columbus, OH

- Authored, refined, and managed Institutional Review Board (IRB) clinical protocols, facilitating effective communication and coordination between biotech companies and clinical trial operations.
- Led data abstraction for real-world evidence (RWE) datasets focused on immunotherapy (IO) treatments, generating a comprehensive clinic-wide clinical dataset.
- Conducted analysis and validation of mutational genomic signatures to predict patient response to immunotherapy in head and neck cancers, contributing to personalized treatment approaches.

**Postdoctoral Research Fellow, Cancer Biology & Epigenetics**  
Ohio State University Comprehensive Cancer Center - James Cancer Hospital

May 2018 – February 2021  
Columbus, OH

*Honors: Pelotonia Institute for Immuno-Oncology, Pelotonia Postdoctoral Scholarship Program - 2 year full salary support*

- Investigated the role of PI3K/AKT signaling pathways in the assembly of RNA complexes within lung cancer cells, contributing to the understanding of cancer biology.
- Pioneered the development and validation of a novel therapeutic agent that disrupts RNA complexes, thereby potentiating the efficacy of immunotherapy treatments.
- Provided mentorship and supervision to three undergraduate research assistants, promoting academic growth and hands-on experience in cancer research.
- Implemented an electronic lab inventory system, optimizing resource management and operational efficiency.

**Tufts Medical Center, Molecular Oncology Research Institute**  
Postdoctoral Research Fellow, Cancer Biology & Epigenetics

Boston, MA  
December 2017 – April 2018

- Successfully executed the initial planning, established the research pipeline, and validated targets related to PI3K/AKT-driven RNA complexes in lung cancer, laying the groundwork for future therapeutic interventions.

## REPRESENTATIVE PUBLICATIONS

Yoshiaki Nakamura, Daisuke Kotani, Saori Mishima, Hiroki Yukami, Jun Watanabe, Naoya Akazawa, Kozo Kataoka, Keiji Hirata, Kentaro Yamazaki, Kun-Huei Yeh, **Laliotis G**, Vasily N. Aushev, Adham Jurdi, Masahito Kotaka, Hideaki Bando, Hiroya Taniguchi, Ichiro Takemasa, Takeshi Kato, Takayuki Yoshino, Eiji Oki. Circulating tumor (ct)DNA as a prognostic biomarker in patients (pts) with resected colorectal cancer (CRC): an updated 24 months (mos) disease free survival (DFS) analysis from GALAXY study. *Annals of Oncology*, 34(S415-S416), 2023 Oct

Sia V. Lindskrog, Karin Birkenkamp-Demtroder, Iver Nordentoft, **Laliotis G**, Philippe Lamy, Emil Christensen, Derrick Renner, Tine G. Andreasen, Naja Lange, Shruti Sharma, Adam C. ElNaggar, Minetta C. Liu, Himanshu Sethi, Alexey Aleshin, Mads Agerbæk, Jørgen B. Jensen, Lars Dyrskjøt; Circulating tumor DNA analysis in advanced urothelial carcinoma: insights from biological analysis and extended clinical follow-up. *Clinical Cancer Research*, 29(23), 4797-4807.

Ajitha Kommalapati, **Laliotis G**, Michael Glover, Grayce Selig, Tamara Mahmood, Sumit Shah, Christopher J. Hoimes, Tyler F. Stewart, Shruti Sharma, Meenakshi Malhotra, Natalia Pajak, Mark Calhoun, Adam ElNaggar, Minetta C. Liu, Arnab Basu, Alan Tan, Matt D. Galsky. Association of Tumor-Informed Minimal Residual Disease (MRD) with Clinical Outcomes for Muscle Invasive Bladder Cancer (MIBC) – A Multicenter Retrospective Real World Analysis. *J Clin Oncol* 41, 2023 (suppl 16; abstr 3050)

Issa M, Klamer BG, Mladkova N, **Laliotis G**, Karivedu V, Bhateja P, Byington C, Dibs K, Pan X, Chakravarti A, Grecula J, Jhawar SR, Mitchell D, Baliga S, Old M, Carrau RL, Rocco JW, Blakaj DM, Bonomi M. Update of a prognostic survival model in head and neck squamous cell carcinoma patients treated with immune checkpoint inhibitors using an expansion cohort. *BMC Cancer*. 2022 Jul 14;22(1):767

## SKILLS

Phase I-III Trial Design | RWE Studies | Regulatory Submissions – IND, MolDx, GCP, ICH, EMEA | Medical & Molecular Oncology Expertise | Healthcare Strategy & Consulting | v Advanced Statistical Analysis – R, Python, Stata, SAS | NGS Bioinformatics Analysis